Stem cell therapy has come a long way since its early days. As an athlete who has undergone it twice, I know that the ...

In recent days, we have seen David Reinbacher start skating again. This is good news for the Canadiens’ prospect as it means that his knee injury (he underwent surgery, as you know, in the fall ...

In recent days, we have seen David Reinbacher start skating again. This is good news for the Canadiens’ prospect as it means that his knee injury (he underwent surgery, as you know, in the fall) is ...

12:20 p.m. ET Late Tuesday, Eli Lilly CEO David Ricks took to the stage at the J.P. Morgan Healthcare Conference to explain his views of the booming GLP-1 space. Earlier in the day, Lilly warned ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

According to one research review, mesenchymal stem cell (MSC) therapy may help reduce or prevent central nervous system (CNS) damage due to MS. Some participants in clinical studies also noted ...

This highlights the important research significance of cell therapy in the field of scleroderma. Figure 1. Illustration of Application of CAR-T Therapy treatment. Mesenchymal stem cells can be derived ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

Background A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet ...

In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...